{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:24:54Z","timestamp":1773188694059,"version":"3.50.1"},"reference-count":11,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&T"],"published-print":{"date-parts":[[2025,4,30]]},"DOI":"10.5582\/ddt.2025.01012","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T22:06:54Z","timestamp":1745878014000},"page":"133-135","source":"Crossref","is-referenced-by-count":4,"title":["Effects of patient age on the therapeutic effects of GIP\/GLP-1 receptor agonists (tirzepatide)"],"prefix":"10.5582","volume":"19","author":[{"given":"Atsushi","family":"Ishimura","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacy Assessment, Hoshi University, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department of Sainokuni Higashi Omiya Medical Center, Saitama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Yabuki","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department of Sainokuni Higashi Omiya Medical Center, Saitama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Nambu T, Murakami T, Matsuda Y, Matsuo K, Yonemitsu S, Muro S, Oki S. Long-term efficacy of liraglutide in the treatment of patients with type 2 diabetes. J Jpn Diabetes Soc. 2014; 57:153-161."},{"key":"2","unstructured":"2. Oshinoi T, Saito M, Oshinoi Y, Nakata M, Ofuchi K, Katoh M. Long-term administration of a GLP-1 receptor agonist liraglutide improves hepatic function and fibrosis in Japanese patients with type 2 diabetes mellitus. Med Consult New Rem. 2019; 56:729-735."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bailey CJ. GIP analogues and the treatment of obesity-diabetes. Peptides. 2020; 125:170202.","DOI":"10.1016\/j.peptides.2019.170202"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Holst JJ, Rosenkilde MM. GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists. J Clin Endocrinol Metab. 2020; 105:e2710-e2716.","DOI":"10.1210\/clinem\/dgaa327"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dutta D, Surana V, Singla R, Aggarwal S, Sharma M. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. Indian J Endocrinol Metab. 2021; 25:475-489.","DOI":"10.4103\/ijem.ijem_423_21"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kanbay M, Copur S, Siriopol D, Yildiz AB, Gaipov A, Raalte DH, Tuttle KR. Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023; 25:3766-3778.","DOI":"10.1111\/dom.15272"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yabe D, Kawamori D, Seino Y, Oura T, Takeuchi M. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy). Diabetes Obes Metab. 2023; 25:398-406.","DOI":"10.1111\/dom.14882"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chen I, Liu C, Chiu J, Hsu C. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2016; 35:592-599.","DOI":"10.1016\/j.clnu.2015.05.003"},{"key":"9","unstructured":"9. Ishimura A, Takizawa Y. Glucagon-like peptide-1 (GLP-1) receptor agonist usage and safety study. Jpn J Appl Ther. 2024; 19:36-42."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kubota M, Yamamoto K, Yoshiyama S. Effect on hemoglobin A1c (HbA1c) and body weight after discontinuation of tirzepatide, a novel glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist: A single-center case series study. Cureus. 2023; 15:e46490.","DOI":"10.7759\/cureus.46490"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ishimura A, Kumakura H. Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function. Drug Discov Ther. 2024; 18:323-324.","DOI":"10.5582\/ddt.2024.01061"}],"container-title":["Drug Discoveries & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/2\/19_2025.01012\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:19:46Z","timestamp":1746850786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/2\/19_2025.01012\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01012","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"article-number":"2025.01012"}}